An in depth understanding of these proteins will enable doctors to predict disease progression and to find the optimal treatment plan for each patient. Vitreous proteomics is a valuable research tool, which makes it possible to learn the biochemistry of retinal diseases and to understand how treatments affect the biochemistry. This knowledge in turn will help develop biomarkers that can assist in predicting disease progression and finding optimal treatments.
NRI is currently involved in the following proteomics projects:
Vitreous Proteomics of Patient with Wet AMD.
The goal of this ongoing study is to understand the biochemistry of the vitreous of patients with wet AMD. This is important to physicians and patients alike because it will lead to better disease management and treatment methods. All of the work is done with the ultimate goal of saving, maintaining or recovering the vision of people affected by the disease.
To Date, we have done numerous research studies, which have suggested that vitreous proteomics may be able to:
- Predict if a patient will respond to anti-VEGF treatments
- Predict if a patient is at risk of developing sub-retinal fluid (a sign of disease progression)
- Assess if a patient should remain on a monthly treatment regime or if their treatments can be extended over longer periods of time (3 months)
Currently we are working on validating the work described above in larger groups of patients, to prove that our findings can be used as disease or treatment biomarkers. Additionally we are working on a study showing that there are significant differences in the levels of vitreous proteins between patients who have classic choroidal neovascularization (Classic CNV) versus those who have retinal angiomatous proliferation (RAP). This study includes over 100 patients and is proving there are strong biological differences between these two sub-types of AMD.
Vitreous Proteomics of Patient with Diabetic Retinopathy
The goal of this ongoing study is to understand the biochemistry of the vitreous of patients with Diabetic Retinopathy, and the biological difference between patients who have non-proliferative and proliferative disease. This is important to physicians and patients alike because it will lead to better disease management and treatment methods. All of the work is done with the ultimate goal of saving, maintaining or recovering the vision of people affected by the disease.
To date we have done studies that have begun to show that there is a difference in the biochemistry of the vitreous in patient with proliferative diabetic retinopathy who have low vision (worse than 20/200) versus those who have better vision (VA better than 20/200). (Sub-link)
Additionally we have begun to find proteins in the vitreous that may assist in predicating when a patient will progress from NPDR to PDR. (Sub-link)
NRI proteomics research has been proudly the recipient of several prestigious grants.
- NIH/ NEI SBIR Phase I Grant 1R43EY021082-01: "Development and Commercialization of Ocular Diagnostic Tests Based on Vitreous Proteomics.”
- HHS/IRS Qualified Therapeutic Discovery Program Grant # 09QTDP27-20181471: Performing research to develop a diagnostic tool to meet unmet needs for Adult Macular Degeneration, which will reduce health care costs and create high quality U.S. Jobs.
Pending Awards and Awards Under Review
- NIH/NEI SBIR Phase II Grant 2R43EY021082-02A1: Development and Commercialization of Ocular Diagnostic Tests Based on Vitreous Proteomics. (Pending Award)
- NIH/NEI R01 Grant 1R01EY023573-01: Vitreous Proteomics to Discover the Biochemical Pathophysiology of Proliferative Diabetic Retinopathy (Under Council Review)
- PCORI Grant # 4071: Assessing the best treatment options for patients with Diabetic Macular Edema (Under Review)